What is the drug class of Coreg (carvedilol)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Coreg (carvedilol) is a beta-blocker with combined alpha- and beta-receptor blocking properties, making it more specifically classified as an alpha/beta-adrenergic blocking agent. According to the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults 1, carvedilol is listed under the category of "Beta blockers—combined alpha- and beta-receptor" with a usual dose range of 12.5–50 mg/day and a daily frequency of 2. This classification is based on its mechanism of action, which involves blocking both beta-1 and beta-2 receptors in the heart and blood vessels, as well as alpha-1 receptors in blood vessels.

The dual mechanism of carvedilol allows it to reduce heart rate and cardiac output while also causing vasodilation, which lowers blood pressure more effectively than traditional beta-blockers. Carvedilol is commonly prescribed for conditions such as hypertension, heart failure, and left ventricular dysfunction following a heart attack. The medication's ability to reduce workload on the heart while improving blood flow makes it particularly valuable for patients with both hypertension and heart failure. Unlike some other beta-blockers, carvedilol has a more favorable metabolic profile, with less negative impact on blood glucose and lipid levels, making it a good option for patients with diabetes or metabolic disorders who require beta-blocker therapy. As noted in the treatment of hypertension in patients with coronary artery disease: a scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension 1, carvedilol may be particularly appealing because of its additional α-blocking properties and more favorable effect on glycemic control.

From the FDA Drug Label

Carvedilol Tablet is a prescription medicine that belongs to a group of medicines called “betablockers” The drug class of Coreg (carvedilol) is beta blockers 2.

  • Key characteristics: nonselective β-adrenergic blocking agent with α1-blocking activity 2. The main point is that Coreg is classified as a beta blocker, which is a group of medicines used to treat various conditions such as high blood pressure and heart failure.

From the Research

Drug Class of Coreg (Carvedilol)

  • Coreg, also known as carvedilol, belongs to a class of drugs known as beta-blockers 3, 4, 5, 6, 7
  • More specifically, carvedilol is a nonselective beta-adrenoceptor blocking vasodilator drug 4
  • It has both beta-blocking and alpha-blocking properties, which distinguishes it from other beta-blockers 4, 6
  • The combination of these properties makes carvedilol useful in the treatment of various cardiovascular disorders, including hypertension, heart failure, and coronary artery disease 4, 6, 7

Mechanism of Action

  • The beta-blocking component of carvedilol inhibits the reflex tachycardia that occurs following alpha-blockade 4
  • The alpha-blocking component of carvedilol may overcome the direct vasoconstrictor consequence of beta 2-blockade 4
  • Carvedilol also has antioxidant properties, which may contribute to its beneficial effects in heart failure 6

Comparison to Other Beta-Blockers

  • Carvedilol has been compared to other beta-blockers, such as metoprolol and bisoprolol, in the treatment of heart failure 3, 7
  • Some studies suggest that carvedilol may be more effective than metoprolol in heart failure, possibly due to its ancillary properties 7

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Beta-blockers and heart failure.

Indian heart journal, 2010

Research

Carvedilol: just another Beta-blocker or a powerful cardioprotector?

Cardiovascular & hematological disorders drug targets, 2006

Research

Carvedilol versus other beta-blockers in heart failure.

Expert opinion on investigational drugs, 2001

Related Questions

What is the next dose increment of Coreg (Carvedilol) after 3.125mg?
What is the next best treatment plan for a 90-year-old female with an ejection fraction (EF) of 48% by Biplane Method of Discs, grade II diastolic dysfunction, moderate mitral valve regurgitation, moderate tricuspid valve regurgitation, and moderate pulmonary hypertension?
What is the indication of an elevated B-type natriuretic peptide (BNP) level?
Is metoprolol (beta blocker) causing nightmares in a patient taking 47.5mg of metoprolol succinate (controlled release) and can it be substituted with bisoprolol (beta blocker)?
What is the appropriate management for an 88-year-old patient with stage 4 Chronic Kidney Disease (CKD) and Congestive Heart Failure (CHF) exacerbation, who presents with increased fatigue, Shortness of Breath (SOB), and weight gain after discharge on torsemide (Generic name: torsemide), a loop diuretic?
What is the treatment for a patient with a right common femoral vein Deep Vein Thrombosis (DVT)?
What is the initial workup for a patient suspected of having pulmonary endometriosis?
What additional antihypertensive medication can be used in a patient with uncontrolled hypertension on Coreg (carvedilol)?
What is the recommended starting dose for Lisinopril (Angiotensin-Converting Enzyme inhibitor) in adults with hypertension?
What is the recommended dose for Hydrochlorothiazide (HCTZ)?
What is the average reduction in Hemoglobin A1c (HbA1c) levels in patients with Type 2 diabetes mellitus (T2DM) following a Mediterranean diet?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.